Dr. Nemunitis is one of the leading investigators for developing early-phase trials aimed at identifying new cancer-specific therapies administered in an outpatient setting. Because of his vision and passion to end HIBM, Dr. Nemunaitis is also active in accelerating the bench to bedside process for HIBM gene therapy.
Dr. Nemunitis received his B.A. Degree in Chemistry & Psychology and earned his M.D. at The Case Western Reserve University,Cleveland, OH. He completed his medical residency at Boston City Hospital, Boston, MA, and a fellowship in Hematology and Oncology at University of Washington School of Medicine and Fred Hutchinson Cancer Research Center, Seattle, WA, after which he served as Research Clinical Associate and Assistant Professor until 1992. Subsequently, was the Director of Hematopoiesis Program, Western Pennsylvania Hospital, Western Pennsylvania Cancer Institute, Pittsburgh, PA, during 1993-2004, and Director of Clinical Research, Texas Oncology, PA, during 1999-2004. From 1995, Dr. Nemunaitis is the Executive Medical Director, Mary Crowley Medical Research Center (MCMRC), where he continues his zealous work against cancer.